BI
Live price temporarily unavailable.
Price history
Biogen (BIIB) is a Health Care company in the S&P 500. Latest news and coverage below.
Recent News (20)
-
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) –4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with…
-
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet
-
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) –4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–
-
Veeva stock gains as Biogen selects Vault CRM globally By Investing.com Veeva stock gains as Biogen selects Vault CRM globally By Investing.com Investing.com Canada
-
-
Veeva Vault CRM Selected by Biogen Unified commercial platform to help speed the delivery of medicines to patients PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has committed t…
-
Biogen Completes Acquisition of RayThera Inc. Lead program now in Phase 1 development Lead program now in Phase 1 development
-
Biogen Completes Acquisition of RayThera Inc. Lead program now in Phase 1 development Lead program now in Phase 1 development
-
-
Why Biogen Stock Topped the Market Today Why Biogen Stock Topped the Market Today
-
Biogen Inc. Q2 2026 Earnings Call Summary Biogen Inc. Q2 2026 Earnings Call Summary
-
Why Biogen Stock Is Resisting a Market Downturn After Earnings Why Biogen Stock Is Resisting a Market Downturn After Earnings
-
Biogen Q2 Earnings Call Highlights Biogen Q2 Earnings Call Highlights
-
Earnings call transcript: Biogen beats Q2 2026 estimates, lifts revenue outlook
Earnings call transcript: Biogen beats Q2 2026 estimates, lifts revenue outlook
-
Biogen Beats Second-Quarter Expectations as Growth Portfolio Drives Revenue Higher Biogen Beats Second-Quarter Expectations as Growth Portfolio Drives Revenue Higher
-
-
-
-
Biogen beats quarterly estimates as newer drugs fuel growth Biogen beats quarterly estimates as newer drugs fuel growth
-
More Health Care stocks
- ABBV AbbVie
- AMGN Amgen
- GILD Gilead Sciences
- INCY Incyte
- MRNA Moderna
- REGN Regeneron Pharmaceuticals
- VRTX Vertex Pharmaceuticals
- A Agilent Technologies